Please assess the completion status of the following clinical trial:

Trial Title: The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed NSCLC, who are deemed to be surgical candidates by standard criteria. Patients with all types of NSCLC (e.g., adenocarcinoma, squamous cell carcinoma) will be allowed to enroll.~2. Patients with Stage IA to IIB disease. Select patients with resectable stage IIIA disease (T3N1, T4N0, T4N1) will also be eligible if approved by the PI.~3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~4. Measurable disease by RECIST 1.1 criteria~5. Mediastinoscopy and/or Endoscopic Bronchial Ultrasound (EBUS) and/or Endoscopic Ultrasound (EUS) for complete surgical staging when clinically indicated~6. Serious, active infections must be controlled. Patients may be enrolled while still on antibiotics as long as clinical signs of active infection have resolved.~7. A signed informed consent document (ICD)~8. Patients 18 years or older~9. Able and willing to take oral medications~Exclusion Criteria:~1. Known preexisting interstitial lung disease, interstitial pulmonary fibrosis, or connective tissue disorder associated lung disease~2. Known N2 nodal disease or distant metastatic disease~3. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization.~4. Patients with any of the following lab values at screening should be excluded: Absolute neutrophil count (ANC) \< 1500 / mm\^3; Platelet count \< 100,000 / mm\^3; Serum creatinine \>/= 1.5 times the upper normal limit or calculated/measured creatinine clearance \</= 60 mL/min; Bilirubin \>/=1.5mg/dL (\> 26 mol/L, SI unit equivalent); Aspartate amino transferase (AST) or Alanine amino transferase (ALT) \>/= three (3) times the upper limit of normal.~5. Active hepatitis B infection, active hepatitis C infection or known HIV carrier.~6. Known or suspected active drug or alcohol abuse~7. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom for example Crohn's disease, malabsorption or CTC grade \>/= 2 diarrhea of any etiology.~8. Baseline (\< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram~9. Patients receiving other investigational agent.~10. History of allergic reactions to anilinoquinazolins like gefitinib, erlotinib, or BIBW2992~11. Uncontrolled intercurrent illness that would preclude a patient from undergoing surgery~12. Psychiatric illness/social situations that would limit compliance with study requirements~13. Pregnant (positive pregnancy test) or lactating~14. Inability to comply with study and/or follow-up procedures~15. Patients who are not surgical candidates or refuse surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBW 2992 (Type: EXPERIMENTAL): BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).